Distributed Flow Scheduling in an Unknown Environment

Flow scheduling tends to be one of the oldest and most stubborn problems in networking. It becomes more crucial in the next generation network, due to fast changing link states and tremendous cost to explore the global structure. In such situation, distributed algorithms often dominate. In this paper, we design a distributed virtual game to solve the flow scheduling problem and then generalize it to situations of unknown environment, where online learning schemes are utilized. In the virtual game, we use incentives to stimulate selfish users to reach a Nash Equilibrium Point which is valid based on the analysis of the `Price of Anarchy'. In the unknown-environment generalization, our ultimate goal is the minimization of cost in the long run. In order to achieve balance between exploration of routing cost and exploitation based on limited information, we model this problem based on Multi-armed Bandit Scenario and combined newly proposed DSEE with the virtual game design. Armed with these powerful tools, we find a totally distributed algorithm to ensure the logarithmic growing of regret with time, which is optimum in classic Multi-armed Bandit Problem. Theoretical proof and simulation results both affirm this claim. To our knowledge, this is the first research to combine multi-armed bandit with distributed flow scheduling.Comment: 10 pages, 3 figures, conferenc

Anti-HIV-1 Activity of a New Scorpion Venom Peptide Derivative Kn2-7

For over 30 years, HIV/AIDS has wreaked havoc in the world. In the absence of an effective vaccine for HIV, development of new anti-HIV agents is urgently needed. We previously identified the antiviral activities of the scorpion-venom-peptide-derived mucroporin-M1 for three RNA viruses (measles viruses, SARS-CoV, and H5N1). In this investigation, a panel of scorpion venom peptides and their derivatives were designed and chosen for assessment of their anti-HIV activities. A new scorpion venom peptide derivative Kn2-7 was identified as the most potent anti-HIV-1 peptide by screening assays with an EC50 value of 2.76 µg/ml (1.65 µM) and showed low cytotoxicity to host cells with a selective index (SI) of 13.93. Kn2-7 could inhibit all members of a standard reference panel of HIV-1 subtype B pseudotyped virus (PV) with CCR5-tropic and CXCR4-tropic NL4-3 PV strain. Furthermore, it also inhibited a CXCR4-tropic replication-competent strain of HIV-1 subtype B virus. Binding assay of Kn2-7 to HIV-1 PV by Octet Red system suggested the anti-HIV-1 activity was correlated with a direct interaction between Kn2-7 and HIV-1 envelope. These results demonstrated that peptide Kn2-7 could inhibit HIV-1 by direct interaction with viral particle and may become a promising candidate compound for further development of microbicide against HIV-1

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

On the Aggregatability of Router Forwarding Tables

Abstract—The rapid growth of global routing tables has raised concerns among many Internet Service Providers. The most immediate concern regarding routing scalability is the size of the Forwarding Information Base (FIB), which seems to be growing at a faster pace than router hardware can support. This paper focuses on one potential solution to this problem – FIB aggregation, i.e., aggregating FIB entries without affecting the forwarding paths taken by data traffic. Compared with alternative solutions to the routing scalability problem, FIB aggregation is particularly appealing because it is a purely local software optimization limited within a router, requiring no changes to routing protocols or router hardware. To understand the feasibility of using FIB aggregation to extend router lifetime, we present several FIB aggregation algorithms and evaluate their performance using routing tables and updates from tens of networks. We find that FIB aggregation can reduce the FIB table size by as much as 70 % with small computational overhead. We also show that the computational overhead can be controlled through various mechanisms. I

On the Aggregatability of Router Forwarding Tables

In this book chapter, the authors first present Optimal Routing Table Constructor (ORTC), an optimal one-time FIB aggregation algorithm that preserves strong forwarding correctness. The authors then present four-level FIB aggregation algorithm(s) that can handle dynamic routing updates while maintaining forwarding correctness. Afterwards, the authors evaluate our algorithms using routing tables from RouteViews, and compare the algorithms with ORTC using routing tables from a Tier-1 ISP. The authors found that ORTC\u27s aggregation ratio is better than the Level 1, Level 2 and Level 3 algorithms, but the Level 4 algorithm has better aggregation ratio than ORTC as they relax the requirement of forwarding correctness. Finally, the authors evaluate the potential impact of introducing extra routable space in the Level 4 algorithm and discuss how to limit such negative impact